Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04152759
Other study ID # BAT-2506-001-CR
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 9, 2019
Est. completion date December 31, 2020

Study information

Verified date November 2019
Source Bio-Thera Solutions
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is a randomized, double-blinded, single-dose, 2-arm parallel, comparative study to evaluate the pharmacokinetics and safety of BAT2506 Injection vs Simponi in healthy chinese male subjects A total of 182 subjects are planned to be included and randomized at a ratio of 1:1 to receive single subcutaneous administration of 50mg BAT2506 Injection or Simponi® (EU-licensed ). The study has a screening period of 14 days. PK blood samples will be collected from subjects to determine the serum concentration of Golimumab, thus to evaluate the change and similarity of the pharmacokinetics of the two study drugs. The investigator will perform safety evaluation for vital signs, physical examinations, injection site reaction, ECG, clinical laboratory tests and adverse events throughout the study. Immunogenicity evaluation (ADA, ADA titration and nAb) will also be evaluated.


Description:

It is a randomized, double-blinded, single-dose, 2-arm parallel, comparative study to evaluate the pharmacokinetics and safety of BAT2506 Injection vs Simponi in healthy chinese male subjects A total of 182 subjects are planned to be included and randomized at a ratio of 1:1 to receive single subcutaneous administration of 50mg BAT2506 Injection or SimponiĀ® (EU-licensed ). The study has a screening period of 14 days. PK blood samples will be collected from subjects to determine the serum concentration of Golimumab, thus to evaluate the change and similarity of the pharmacokinetics of the two study drugs. The investigator will perform safety evaluation for vital signs, physical examinations, injection site reaction, ECG, clinical laboratory tests and adverse events throughout the study. Immunogenicity evaluation (ADA, ADA titration and nAb) will also be evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 182
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Healthy male subjects aged18 and 50 years inclusive; BMI between 18 and 28 kg/m2 and body weight between 50 and 80 kg. - Physical examinations and vital signs are normal or abnormal without clinical significance. - Abdominal color Doppler ultrasound, laboratory tests, etc. are normal or abnormal without clinical significance. Exclusion Criteria: - Any current or history of severe allergic reaction to foods or drugs and History of allergy to study products. - Having severe injuries or surgery or fractures within 4 weeks before enrollment,or to receive surgery during the study. - Having clinically significantclinical history abnormalities or other clinically indicated diseases (including but not limited to gastrointestinal, renal, liver, neurological, hematological, endocrine, tumor, lung, immune, mental or cardiovascular diseases). - Having malignant tumor (excluding basal cell carcinoma who has undergone resection). - Having clinically significant chronic or acute infections at screening/incorporation; or active infections,Includes acute and chronic infections as well as local infections (bacteria, viruses, parasites, fungi or other opportunities) Sexually infected pathogen). - Having a history of tuberculosis or latent tuberculosis or clinical manifestations suspected of being tuberculosis(including But not limited to tuberculosis). - Having been exposed to tuberculosis or/and suspected tuberculosis symptoms and/or signs within 3 months before screening. - Having used simponi,or any anti-tumor necrosis factor (TNF-a) biologic preparation or any biological products within 6 months before enrollment or monoclonal antibodies within a month. - Having used drugs within 30 days before enrollment (including but not limited to prescription drugs, Chinese medicine, non-prescription drugs). - Having vaccinated active / attenuated vaccine within 12 weeks before screening or planned to vaccinate active /attenuated vaccine the during the study. - Having a history of hypertension or systolic blood pressure = 140 mmHg, or diastolic blood pressure = at screening/inclusion90 mmHg, and it is judged abnormalities with clinical significance. - Electrocardiogram (ECG) examination abnormalities with clinical significance; - Having positive detection of golimumab anti-drug antibody (ADA) during screening. - Chest orthotopic examination abnormalities with clinical significance. - Tuberculosis enzyme-linked immunospot assay (T-SPOT. TB) positive test, - Having any alcoholic products within 24 hours prior to the use of the study drug. - A drug abuse test positive or a history of drug abuse over the past five years.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Drug: BAT2506 injection Other Names: Simponi(EU-licensed)
Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed). Other Names: Simponi(EU-licensed)

Locations

Country Name City State
China The First Bethune Hospital of Jilin University Changchun Jilin

Sponsors (1)

Lead Sponsor Collaborator
Bio-Thera Solutions

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetics Endpoint:AUC0-t Pharmacokinetics Endpoint:AUC0-t 0-71days
Primary Pharmacokinetics Endpoint:Cmax Pharmacokinetics Endpoint:Cmax 0-71days
Secondary Pharmacokinetics Endpoint:AUC0-inf Pharmacokinetics Endpoint:AUC0-inf 0-71days
See also
  Status Clinical Trial Phase
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT01925768 - Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis Phase 3
Completed NCT01892436 - Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis Phase 3
Completed NCT01212770 - PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Phase 3
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT01212757 - PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Phase 3
Completed NCT03953378 - CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
Recruiting NCT02572700 - Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
Completed NCT02556034 - Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02188654 - Metformin in Psoriatic Arthritis N/A
Completed NCT02164214 - Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? Phase 3
Completed NCT01392326 - Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) Phase 3
Completed NCT01083693 - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs N/A
Not yet recruiting NCT00517101 - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy N/A
Completed NCT00133315 - TNFalfa Blocking Treatment of Spondylarthropathies Phase 4
Completed NCT00659412 - A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis Phase 2
Completed NCT00946686 - To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions Phase 1
Not yet recruiting NCT06059430 - Cohort Project of Patients With Inflammatory Rheumatism
Completed NCT03736161 - Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis Phase 3